INNODIA was launched on Nov 1st 2015 in response to the first call of the Innovative Medicines Initiative (IMI) under IMI2 by an international consortium including academia, medium-sized enterprises (SME), large pharmaceutical companies and patient organizations.
33 partners including 26 academic institutes and clinics, 4 EFPIA partners, 2 patient organizations and one SME have joined forces to form a €36 Mio IMI-supported public private partnership (PPP) to significantly improve the understanding of type 1 diabetes (T1D) and work towards better therapies for preventing and curing this devastating disease.
The INNODIA consortium is aiming to advance in a decisive way how to predict, stage, evaluate and prevent the onset and progression of type 1 diabetes. This will be achieved by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. These tools will help to distinguish and understand distinctive paths of ontogeny and progression in this heterogeneous disease at the cellular and molecular level, thus impacting the future management of T1D patients and at risk individuals.Download PDF